Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

BTK

RBC: BTK · Substrate: pEY ·

Top inhibitors

MeasuredDerived
DrugInhibition %Gini
Bosutinib99.30.55
Canertinib99.30.67
Dasatinib99.30.70
Ibrutinib98.80.72
Nintedanib98.00.61
Pirtobrutinib97.70.66
Remibrutinib97.70.72
Zanubrutinib97.40.79
Mobocertinib97.40.76
Osimertinib96.30.73
Acalabrutinib95.90.67
Entrectinib95.10.67
Neratinib93.90.60
Repotrectinib93.70.61
Afatinib88.60.71

Known variants

Cancer associations

MutationCancer typeOrganSource
C481Slymphoid_neoplasm_haematopoietic_and_lymphoid_tissueBlood/Lymphatic Systemhttps://doi.org/10.1093/nar/gkaa945
P190Kcarcinoma_lungLunghttps://doi.org/10.1093/nar/gkaa945
T474Icarcinoma_large_intestineLarge Intestinehttps://doi.org/10.1093/nar/gkaa945
T474Ilymphoid_neoplasm_haematopoietic_and_lymphoid_tissueBlood/Lymphatic Systemhttps://doi.org/10.1093/nar/gkaa945
E41Kchronic_lymphocytic_leukemiaBlood/Lymphatic Systemhttps://www.cancer.gov/tcga.
E41Kanaplastic_large_cell_lymphomaBlood/Lymphatic Systemhttps://doi.org/10.1158/2159-8290.CD-12-0095
Y485Fchronic_lymphocytic_leukemiaBlood/Lymphatic Systemhttps://depmap.org/portal.
Y485Fanaplastic_large_cell_lymphomaBlood/Lymphatic Systemhttps://www.cancer.gov/tcga.
Open in new tab